EU Regulation 396/2005: Pesticide Residue Testing and the Critical Role of QuEChERS Evaporation in Food Safety

<div><div><p><strong>Researchers led by </strong><a target="_blank" rel="noopener noreferrer" href="https://kudova.group.uochb.cz/en"><strong>Eva Kudová</strong></a><strong> from IOCB Prague and Jitka Viktorová from UCT Prague have identified new androstane-based steroid derivatives that can significantly improve the effectiveness of existing antibiotics against multidrug-resistant </strong><i><strong>Staphylococcus aureus</strong></i><strong>.</strong></p></div></div><div><p>The team screened dozens of natural steroidal hormones and synthetic derivatives to see whether they could block bacterial efflux pumps – mechanisms that bacteria use to eject antibiotics and survive treatment. Two compounds emerged as particularly promising: they inhibited efflux pumps and lowered the effective doses of antibiotics such as ciprofloxacin and erythromycin.</p><p>Further analysis showed that one of the compounds also suppressed genes linked to bacterial virulence. Another key finding is that the most active molecules are non-toxic to human immune cells and showed no detectable endocrine activity, suggesting a favorable safety profile.</p><p>These findings support the idea that rationally designed steroid-based molecules could act as antibiotic adjuvants, helping existing drugs overcome bacterial resistance.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/IOCB_Prague_Steroidal_hormones_and_neurosteroids_novel_therapeutic_strategies_in_bacterial_infections_8e5d2a7b48.jpg" alt="IOCB Prague: Steroidal hormones and neurosteroids – novel therapeutic strategies in bacterial infections" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_IOCB_Prague_Steroidal_hormones_and_neurosteroids_novel_therapeutic_strategies_in_bacterial_infections_8e5d2a7b48.jpg 222w," sizes="100vw" width="1258" height="886"></p><blockquote><h4><strong>Original Article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://www.sciencedirect.com/science/article/pii/S0223523426001613?via%3Dihub"><strong>Steroidal hormones and neurosteroids - novel therapeutic strategies in bacterial infections: Design, synthesis, and biological evaluation</strong></a></h4><p>Daniela Brdová, Bára Křížkovská, Jan Špaček, Zdeněk Míchal, Eva Jablonská, Ondřej Strnad, Hana Chodounská, Eszter Szánti-Pintér, Marina Morozovová, Václav Hanžl, Jan Tkadlec, Martijn Riool, Jan Lipov, Jitka Viktorová, Eva Kudová&nbsp;</p><p><i><strong>Eur. J. Med. Chem., 2026, 308, 118716</strong></i></p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1016/j.ejmech.2026.118716">https://doi.org/10.1016/j.ejmech.2026.118716</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>The global rise of antibiotic resistance necessitates novel therapeutic strategies for infectious diseases. Inhibition of bacterial efflux pumps, which contribute to multidrug resistance, represents a promising approach to restore or even increase the efficacy of existing antibiotics. Using fluorescence-based ethidium bromide accumulation, broth microdilution, and checkerboard assays, we evaluated 26 endogenous steroidal hormones and neurosteroids, along with 30 synthetic derivatives, for their ability to enhance antibiotic susceptibility in multidrug-resistant <i>Staphylococcus aureus</i>. Structure-activity relationship analysis identified compounds <strong>13</strong> and <strong>16</strong> as lead candidates, exhibiting strong efflux pump inhibition and marked reductions in the minimum inhibitory concentrations of ciprofloxacin and erythromycin. Both compounds showed additive effects in checkerboard assays. Modifications at C-3 (polar substitution) and C-17 (3α,5β-stereochemistry and nonpolar substitution) were essential for potent efflux inhibition and sensitization, although these modifications were not additive when combined. Transcriptome analysis further revealed that compound <strong>13</strong> significantly downregulated <i>S. aureus</i> virulence-associated genes when administered alone or in combination with antibiotics. Cytotoxicity assessment in human peripheral blood mononuclear cells and receptor transactivation assays for estrogen, androgen, and progesterone receptors indicated that the most active derivatives were non-toxic and lacked detectable endocrine activity, suggesting a favorable safety profile. Overall, these findings support the concept that rationally designed andostane-based steroidal scaffolds can function as competitive bacterial efflux pump inhibitors and serve as potential antibiotic adjuvants to mitigate efflux-mediated resistance.</p><h4><strong>Instrumentation</strong></h4><h5><strong>Structural characterization</strong></h5><ul><li><strong>AVANCE III 400 MHz NMR spectrometer</strong> (Bruker)</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/library?mainauthorItems=3&amp;search=LTQ+Orbitrap+XL"><strong>LTQ Orbitrap XL HRMS</strong></a> (Thermo Fisher Scientific, ESI)</li></ul></div>

Steroidal hormones and neurosteroids – novel therapeutic strategies in bacterial infections

<p><strong>Metformin is currently the first-line oral drug of choice for the treatment of type 2 diabetes. It reduces glucose production in the liver, improves tissue sensitivity to insulin, and does not cause weight gain or hypoglycemia, which sets it apart from some other antidiabetic drugs. Moreover, its long-term beneficial effects on the risk of cardiovascular complications and mortality in people with type 2 diabetes have been well established. Researchers from the Institute of Physiology CAS (IPHYS) have identified a new group of blood metabolites that could help physicians objectively monitor whether patients with type 2 diabetes are taking their metformin as prescribed.</strong></p><h4><strong>New biomarkers for metformin use</strong></h4><p>A team led by Tomáš Čajka from the Laboratory of Translational Metabolism at IPHYS analyzed plasma samples from <strong>637 patients with type 2 diabetes treated with metformin</strong> and <strong>143 non-diabetic controls</strong> using advanced metabolomics and lipidomics. Among 614 detected metabolites, they identified five from the group of <strong>N-lactoyl-amino acids </strong>(e.g. N‑lactoyl-phenylalanine), which had previously been seen as unknown signals due to missing reference spectra in databases. The levels of these metabolites in the blood closely reflected the plasma concentrations of metformin. In patients with the highest metformin exposure, the concentrations of these metabolites were up to 7.2 times higher than in controls.</p><h4><strong>A sensitive “fingerprint” of the drug’s effect</strong></h4><p>N-Lactoyl-amino acids are formed in cells by combining lactate and amino acids, thus reflecting the metformin-induced changes in cellular energy metabolism. “<i>Importantly, even though they occur in plasma only at nanomolar concentrations, they reliably distinguish patients who take metformin regularly from those who take it irregularly or not at all</i>,” emphasizes T. Čajka.</p><h4><strong>Metabolomics in practice and international collaboration</strong></h4><p>The study also provides a detailed description of broader metabolic changes in type 2 diabetes, including increases in lactate, organic acids, and branched-chain amino acids, as well as extensive remodelling of the lipid profile. In addition to T. Čajka’s team, collaborators from the Institute for <strong>Clinical and Experimental Medicine in Prague</strong> and the <strong>West Coast Metabolomics Center</strong> (University of California, Davis) also participated in the study.</p><p>The results demonstrate that advanced metabolomics approaches developed at IPHYS within the <strong>CarDia project</strong> can find highly practical applications both in clinical studies and in personalized monitoring of treatment in patients with diabetes.</p><blockquote><h4><strong>The original article</strong></h4><h4><a target="_blank" rel="noopener noreferrer" href="https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.70205"><strong>Untargeted Metabolomics Identifies N-Lactoyl-Amino Acids as Dose-Responsive Plasma Biomarkers of Metformin Adherence in Type 2 Diabetes</strong></a></h4><p>Tomas Cajka, Jiri Hricko, Lucie Rudl Kulhava, Michaela Paucova, Michaela Novakova, Veronika Hola, Stanislava Rakusanova, Oliver Fiehn, Vojtech Skop, Ivana Lankova, Iva Miskova, Terezie Pelikanova, Martin Haluzik</p><p>Clin Pharmacol Ther, 119: 1057-1069</p><p><a target="_blank" rel="noopener noreferrer" href="https://doi.org/10.1002/cpt.70205">https://doi.org/10.1002/cpt.70205</a></p><h6>licensed under <a target="_blank" rel="noopener noreferrer" href="https://creativecommons.org/licenses/by/4.0/"><strong>CC-BY 4.0</strong></a></h6></blockquote><h4><strong>Abstract</strong></h4><p>Metformin is the most widely prescribed antidiabetic drug, yet adherence remains difficult to objectively assess. Using untargeted metabolomics and lipidomics, we analyzed plasma from 637 patients with type 2 diabetes (T2D) with confirmed metformin use and 143 nondiabetic controls, annotating 614 metabolites. Patients were stratified by plasma metformin into sub-therapeutic, therapeutic, and supra-therapeutic groups, and associations were evaluated by multiple linear regression and composite metabolite ranking. Five previously unannotated features were structurally identified as N-lactoyl-amino acids, whose levels correlated strongly with plasma metformin (ρ = 0.42–0.55, P &lt; 0.0001) and increased up to 7.2-fold in the supra-therapeutic group (&gt; 2000 ng/mL). While N-lactoyl-amino acids were consistently detected in the nanomolar range, they still displayed robust and dose-dependent associations with metformin. Broader metabolic changes in T2D included elevated lactate, organic acids, and branched-chain amino acids, together with reduced urea cycle metabolites. Lipidomics showed increases in saturated triacylglycerols and diacylglycerols and decreases in cholesteryl esters, sphingomyelins, and phospholipids. These findings establish N-lactoyl-amino acids as robust, dose-responsive plasma biomarkers of metformin exposure. Despite being up to four orders of magnitude less abundant than their amino acid precursors, they sensitively reflect mitochondrial lactate overflow and pharmacodynamic adaptation, offering objective assessment of adherence.</p>

New blood biomarkers reveal how faithfully diabetes patients take metformin

Article

Product

Environment

Food

Health

Scientific article

Science and research

Laboratories

The Czech Academy of Sciences (CAS) was established by Act No. 283/1992 Coll. as the Czech successor of the former Czechoslovak Academy of Sciences. It is set up as a complex of 54 public research institutions.

Czech Academy of Sciences

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. 

Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

Phenomenex Biozen SEC-3 LC columns

High inertness and particle consistency of both Biozen™ SEC columns drives greater reproducibility from injection-to-injection. 

<p><strong>High inertness and particle consistency </strong>of both Biozen™ SEC columns drives greater reproducibility from injection-to-injection. Combine this with the bioinert <strong>BioTi hardware</strong> and good aggregate recovery is no longer something that you’re missing out on.</p><p><strong>Biozen SEC columns provide:</strong></p><ul><li>High efficiency on both HPLC and UHPLC</li><li>Extreme inertness and robustness</li><li>Finely tuned high and low MS separation windows</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_SEC_3_3a6e232271.webp" alt="Phenomenex: Biozen SEC-3" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_SEC_3_3a6e232271.webp 245w," sizes="100vw" width="500" height="150"></p><ul><li><strong>Separation Mode:</strong> Gel Filtration Chromatography (GFC)</li><li><strong>Particle Size:</strong> 1.8</li><li><strong>Recommended Use:</strong> High molecular weight (HMW) separation range of 10 k – 700 kDa</li></ul><h3><strong>Phenomenex Biozen Biologics LC Columns</strong></h3><p>With a new titanium <strong>BioTi™</strong> biocompatible <strong>hardware</strong> to minimize priming, <strong>four particle platforms</strong> for optimal versatility and <strong>nine particle chemistries</strong> to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns for <strong>protein analysis</strong> are seamlessly designed to bring peace of mind to your analysis of biologics through:</p><ul><li>Charge Variant Analysis</li><li>Aggregate Analysis</li><li>Peptide Mapping</li><li>Intact Mass Analysis</li><li>Intact and Subunit Analysis</li><li>Glycan Analysis</li><li>Peptide Quantitation</li><li>Drug Antibody Ratio (DAR)</li><li>Oligonucleotide Characterization</li></ul><h3><strong>Biocompatible Flow Path with BioTi™ Hardware</strong></h3><p>Keep your mind at ease knowing that we’ve minimized the need for priming with a new titanium infused biocompatible hardware and frit that doesn’t interfere with protein or peptide integrity!</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Bio_Ti_Hardware_991fb53395.jpg" alt="Phenomenex: BioTi Hardware" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Bio_Ti_Hardware_991fb53395.jpg 245w," sizes="100vw" width="1378" height="426"></p><h3><strong>4 Advanced Particle Platforms</strong></h3><p>All four of the Biozen particle platforms were individually designed and built by Phenomenex to take advantage of integral levels of performance, ruggedness, and reproducibility for protein characterization applications. Individually, each platform differs in the proprietary processing techniques used to control particle size and morphology.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg" alt="Phenomenex: Advanced Particle Platforms" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg 245w," sizes="100vw" width="1439" height="868"></p>

Phenomenex Biozen SEC-2 LC columns

Biozen SEC columns are extremely inert, high density fully porous particle with high efficiency and low molecular weight separation range.

<p><strong>Biozen SEC columns</strong> are extremely inert, high density fully porous particle with high efficiency and low molecular weight (LMW) <strong>separation range</strong> of <strong>1 k – 450 kDa</strong>.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_SEC_3_3a6e232271.webp" alt="Phenomenex: Biozen SEC-2" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_SEC_3_3a6e232271.webp 245w," sizes="100vw" width="500" height="150"></p><ul><li><strong>Separation Mode:</strong> Gel Filtration Chromatography (GFC)</li><li><strong>Particle Size:</strong> 1.8</li><li><strong>Recommended Use:</strong> Low molecular weight (LMW) separation range of 1 k – 450 kDa</li></ul><h3><strong>Phenomenex Biozen Biologics LC Columns</strong></h3><p>With a new titanium <strong>BioTi™</strong> biocompatible <strong>hardware</strong> to minimize priming, <strong>four particle platforms</strong> for optimal versatility and <strong>nine particle chemistries</strong> to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns for <strong>protein analysis</strong> are seamlessly designed to bring peace of mind to your analysis of biologics through:</p><ul><li>Charge Variant Analysis</li><li>Aggregate Analysis</li><li>Peptide Mapping</li><li>Intact Mass Analysis</li><li>Intact and Subunit Analysis</li><li>Glycan Analysis</li><li>Peptide Quantitation</li><li>Drug Antibody Ratio (DAR)</li><li>Oligonucleotide Characterization</li></ul><h3><strong>Biocompatible Flow Path with BioTi™ Hardware</strong></h3><p>Keep your mind at ease knowing that we’ve minimized the need for priming with a new titanium infused biocompatible hardware and frit that doesn’t interfere with protein or peptide integrity!</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Bio_Ti_Hardware_991fb53395.jpg" alt="Phenomenex: BioTi Hardware" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Bio_Ti_Hardware_991fb53395.jpg 245w," sizes="100vw" width="1378" height="426"></p><h3><strong>4 Advanced Particle Platforms</strong></h3><p>All four of the Biozen particle platforms were individually designed and built by Phenomenex to take advantage of integral levels of performance, ruggedness, and reproducibility for protein characterization applications. Individually, each platform differs in the proprietary processing techniques used to control particle size and morphology.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg" alt="Phenomenex: Advanced Particle Platforms" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg 245w," sizes="100vw" width="1439" height="868"></p>

Phenomenex Biozen dSEC-2 LC columns

Biozen dSEC columns use low-pore silica with a proprietary hydrophilic diol bond to prevent silica-protein interactions.

<p><strong>Advanced SEC Silica Particle Technology and Surface Chemistry for Characterizing Biomolecules</strong></p><p>The <strong>Biozen dSEC columns</strong> are packed with low pore volume silica coupled with a proprietary hydrophilic diol-type bonded surface chemistry that prevents the silica surface from interacting with <strong>protein samples</strong>.</p><ul><li>Exceptionally Robust, Pore Controlled SEC Particle</li><li>Extreme Stability and Exceptional Lifetime</li><li>Reproducible Separations</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_dsec_63af9af237.webp" alt="Phenomenex: Biozen-dSEC-2" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_dsec_63af9af237.webp 245w," sizes="100vw" width="500" height="150"></p><ul><li><strong>Separation Mode:</strong> Gel Filtration Chromatography (GFC)</li><li><strong>Pore size</strong>: 200</li><li><strong>Particle Size:</strong> 1.8, 3</li><li><strong>Recommended Use:</strong> Analysis of monoclonal antibodies, biosimilars and other biomolecules by using specific molecular weights with improved column lifetimes and recovery</li></ul><h4><strong>Biozen SEC Proprietary Silica Particle Technology</strong></h4><p>The Biozen dSEC columns are packed with low pore volume silica coupled with a proprietary hydrophilic diol-type bonded surface chemistry that prevents the silica surface from interacting with protein samples.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_SEC_Proprietary_Silica_Particle_Technology_502218b910.jpg" alt="Phenomenex: Biozen SEC Proprietary Silica Particle Technology" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_SEC_Proprietary_Silica_Particle_Technology_502218b910.jpg 245w," sizes="100vw" width="1448" height="469"></p><h4><strong>Improved Column Lifetime and Performance Stability</strong></h4><p>Phenomenex’s optimized SEC column loading technology has significantly improved the overall packing density and silica distribution of the columns leading to improved chromatographic lifetime and stability.</p><h4><strong>New Standard for Platform SEC Methods</strong></h4><p>Whether IgG2 or IgG4 isotypes, bispecifics, or Fc-Fusions, dSEC-2 provides excellent separation and sample recovery for many different classes of antibodies and related recombinant proteins.</p><h3><strong>Phenomenex Biozen Biologics LC Columns</strong></h3><p>With a new titanium <strong>BioTi™</strong> biocompatible <strong>hardware</strong> to minimize priming, <strong>four particle platforms</strong> for optimal versatility and <strong>nine particle chemistries</strong> to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns for <strong>protein analysis</strong> are seamlessly designed to bring peace of mind to your analysis of biologics through:</p><ul><li>Charge Variant Analysis</li><li>Aggregate Analysis</li><li>Peptide Mapping</li><li>Intact Mass Analysis</li><li>Intact and Subunit Analysis</li><li>Glycan Analysis</li><li>Peptide Quantitation</li><li>Drug Antibody Ratio (DAR)</li><li>Oligonucleotide Characterization</li></ul><h3><strong>Biocompatible Flow Path with BioTi™ Hardware</strong></h3><p>Keep your mind at ease knowing that we’ve minimized the need for priming with a new titanium infused biocompatible hardware and frit that doesn’t interfere with protein or peptide integrity!</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Bio_Ti_Hardware_991fb53395.jpg" alt="Phenomenex: BioTi Hardware" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Bio_Ti_Hardware_991fb53395.jpg 245w," sizes="100vw" width="1378" height="426"></p><h3><strong>4 Advanced Particle Platforms</strong></h3><p>All four of the Biozen particle platforms were individually designed and built by Phenomenex to take advantage of integral levels of performance, ruggedness, and reproducibility for protein characterization applications. Individually, each platform differs in the proprietary processing techniques used to control particle size and morphology.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg" alt="Phenomenex: Advanced Particle Platforms" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg 245w," sizes="100vw" width="1439" height="868"></p>

Phenomenex Biozen dSEC-7 LC columns

dSEC-7 optimizes dimensions to save sample, speed up runs, and enhance resolution for AAVs and large biomolecule separations.

<p><strong>AAV and Large Biomolecule Aggregate Analysis​</strong></p><p><strong>Biozen dSEC-7 columns</strong> are packed with <strong>700 Å large pore silica</strong> coupled with a proprietary hydrophilic diol-type bonded surface chemistry that ensures silica surface interactions are mitigated. Designed with optimized column dimensions, dSEC-7 conserves valuable sample consumption, facilitates faster run times, and maximizes resolution for AAVs and large biomolecule separations.</p><p><strong>Robust and reliable aggregate analysis:</strong></p><ul><li>Baseline resolution of monomer/aggregate species through 700 Å pore size</li><li>Reduction in sample consumption by up to 90 % compared to traditional SEC columns</li><li>Reduction in method times by up to 50 % when compared to traditional SEC columns</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_dsec_63af9af237.webp" alt="Phenomenex: Biozen-dSEC-7" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_dsec_63af9af237.webp 245w," sizes="100vw" width="500" height="150"></p><ul><li><strong>Separation Mode:</strong> Gel Filtration Chromatography (GFC)</li><li><strong>Pore size</strong>: 700</li><li><strong>Recommended Use:</strong> Aggregate analysis of AAVs and other large biomolecules using specific molecular weights that conserves sample consumption, facilitates faster run times, and maximizes resolution.</li></ul><h4><strong>An SEC Column for AAV Aggregate Analysis</strong></h4><figure class="image"><img style="aspect-ratio:668/575;" src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_d_SEC_7_Column_b307c4217d.jpg" alt="Phenomenex: Biozen dSEC-7 Column" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_d_SEC_7_Column_b307c4217d.jpg 182w," sizes="100vw" width="668" height="575"></figure><h4><strong>Biozen dSEC-7 Features</strong></h4><h5><strong>Improved Loading</strong></h5><ul><li>dSEC-7 addresses the challenge of aggregate analysis by offering accurate detection and separation with injections as low as 0.5 µL. Unlike traditional methods that demand large sample volumes, dSEC-7 conserves valuable samples, allowing for replicate analyses and ensuring availability for other CQA tests.</li></ul><h5><strong>Mobile Phase Flexibility</strong></h5><ul><li>dSEC-7’s particle properties facilitate robust separation of monomer from aggregate species, regardless of which mobile phase best suits your sample. This ensures reproducible results while accommodating unique sample demands, easing the burden of method condition optimization during development.</li></ul><h5><strong>Serotype Versatility</strong></h5><ul><li>With its robust performance and 700 Å pore size, dSEC-7 effectively resolves monomer from aggregate peaks across various AAV serotypes. This capability is crucial for evaluating appropriate serotype candidates, each varying in its unique tissue and cell tropisms, to ensure desired therapeutic outcomes are achieved.</li></ul><h5><strong>Instrument Agnostic Performance</strong></h5><ul><li>Despite differences in dwell volume and dispersion across various sites and departments, dSEC-7 consistently delivers robust and reproducible performance across commercially available LC instrumentation. This ensures reliable results regardless of variations in equipment, setup, or location.</li></ul><h5><strong>Outperforms Trending Solutions</strong></h5><ul><li>dSEC-7 excels in providing superior resolution over market alternatives, particularly when characterizing higher-level aggregates in AAV analysis. Unlike current market solutions with insufficient particle pore size, dSEC-7 ensures accurate and reproducible separation of AAV monomer from aggregates.</li></ul><h5><strong>Enhanced Detector Flexibility</strong></h5><ul><li>Conquer sample limitations using SEC-FLR for heightened sensitivity, SEC-MALS for precise molecular weight determination, or SEC-UV for routine analysis. Achieving comprehensive AAV characterization insights by transferring methods across detector technologies with unique benefits is now seamless.</li></ul><h3><strong>Phenomenex Biozen Biologics LC Columns</strong></h3><p>With a new titanium <strong>BioTi™</strong> biocompatible <strong>hardware</strong> to minimize priming, <strong>four particle platforms</strong> for optimal versatility and <strong>nine particle chemistries</strong> to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns for <strong>protein analysis</strong> are seamlessly designed to bring peace of mind to your analysis of biologics through:</p><ul><li>Charge Variant Analysis</li><li>Aggregate Analysis</li><li>Peptide Mapping</li><li>Intact Mass Analysis</li><li>Intact and Subunit Analysis</li><li>Glycan Analysis</li><li>Peptide Quantitation</li><li>Drug Antibody Ratio (DAR)</li><li>Oligonucleotide Characterization</li></ul><h3><strong>Biocompatible Flow Path with BioTi™ Hardware</strong></h3><p>Keep your mind at ease knowing that we’ve minimized the need for priming with a new titanium infused biocompatible hardware and frit that doesn’t interfere with protein or peptide integrity!</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Bio_Ti_Hardware_991fb53395.jpg" alt="Phenomenex: BioTi Hardware" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Bio_Ti_Hardware_991fb53395.jpg 245w," sizes="100vw" width="1378" height="426"></p><h3><strong>4 Advanced Particle Platforms</strong></h3><p>All four of the Biozen particle platforms were individually designed and built by Phenomenex to take advantage of integral levels of performance, ruggedness, and reproducibility for protein characterization applications. Individually, each platform differs in the proprietary processing techniques used to control particle size and morphology.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg" alt="Phenomenex: Advanced Particle Platforms" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg 245w," sizes="100vw" width="1439" height="868"></p>

Phenomenex Biozen dSEC-1 LC columns

Phenomenex Biozen dSEC-1 is a high-resolution SEC column for peptide therapeutics, delivering fast, reproducible aggregate analysis with improved peak shape and compatibility with SEC-MS and SEC-MALS.

<h4><strong>High-Resolution Aggregate Analysis for Peptide Therapeutics</strong></h4><p>Biozen dSEC-1 columns are engineered to meet the growing demand for aggregate analysis in peptide therapeutics and mid-sized biologics. Packed with 90 Å small pore silica and featuring inert diol-based surface chemistry, dSEC-1 delivers enhanced resolution for low and high molecular weight peptide aggregates. Its robust design ensures reproducibility and compatibility with advanced workflows like SEC-MS and SEC-MALS.</p><h5><strong>Robust Performance for Peptide Aggregate Analysis</strong></h5><ul><li>High resolution for low/high MW peptide aggregates (1–50 kDa)</li><li>Reproducible, and fast analysis with extended column lifetime</li><li>Improved peak asymmetry by up to 40%</li><li><strong>Recommended Use: </strong>Analysis of peptides, protein fragments, and small biologics with reduced analysis times and improved column lifetimes.</li></ul><h4><strong>Aggregate and Monomer Separation in Liraglutide Formulations</strong></h4><ul><li>Baseline resolution of monomer and two aggregates achieved in under 10 minutes</li><li>Exceptional reproducibility with retention time RSD ≤ 0.08% and peak area RSD ≤ 0.01%</li><li>Clear detection at low levels with S/N ratios of 13, 75, and 10,917 for aggregates and monomer</li></ul><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_separation_in_liraglutide_formulations_3_b0d97cd01f.jpg" alt="Phenomenex: Aggregate and Monomer Separation in Liraglutide Formulations" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_separation_in_liraglutide_formulations_3_b0d97cd01f.jpg 245w," sizes="100vw" width="938" height="307"></p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_separation_in_liraglutide_formulations_2_035bfea3bc.jpg" alt="Phenomenex: Aggregate and Monomer Separation in Liraglutide Formulations" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_separation_in_liraglutide_formulations_2_035bfea3bc.jpg 245w," sizes="100vw" width="1700" height="1050"></p><h3><strong>Biozen SEC Proprietary Silica Particle Technology</strong></h3><p>The Biozen dSEC columns are packed with low pore volume silica coupled with a proprietary hydrophilic diol-type bonded surface chemistry that prevents the silica surface from interacting with protein samples.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Biozen_SEC_Proprietary_Silica_Particle_Technology_502218b910.jpg" alt="Phenomenex: Biozen SEC Proprietary Silica Particle Technology" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Biozen_SEC_Proprietary_Silica_Particle_Technology_502218b910.jpg 245w," sizes="100vw" width="1448" height="469"></p><h4><strong>Improved Column Lifetime and Performance Stability</strong></h4><p>Phenomenex’s optimized SEC column loading technology has significantly improved the overall packing density and silica distribution of the columns leading to improved chromatographic lifetime and stability.</p><h4><strong>New Standard for Platform SEC Methods</strong></h4><p>Whether IgG2 or IgG4 isotypes, bispecifics, or Fc-Fusions, dSEC-2 provides excellent separation and sample recovery for many different classes of antibodies and related recombinant proteins.</p><h3><strong>Phenomenex Biozen Biologics LC Columns</strong></h3><p>With a new titanium <strong>BioTi™</strong> biocompatible <strong>hardware</strong> to minimize priming, <strong>four particle platforms</strong> for optimal versatility and <strong>nine particle chemistries</strong> to maximize selectivity and sensitivity, Biozen UHPLC/HPLC columns for <strong>protein analysis</strong> are seamlessly designed to bring peace of mind to your analysis of biologics through:</p><ul><li>Charge Variant Analysis</li><li>Aggregate Analysis</li><li>Peptide Mapping</li><li>Intact Mass Analysis</li><li>Intact and Subunit Analysis</li><li>Glycan Analysis</li><li>Peptide Quantitation</li><li>Drug Antibody Ratio (DAR)</li><li>Oligonucleotide Characterization</li></ul><h3><strong>Biocompatible Flow Path with BioTi™ Hardware</strong></h3><p>Keep your mind at ease knowing that we’ve minimized the need for priming with a new titanium infused biocompatible hardware and frit that doesn’t interfere with protein or peptide integrity!</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Bio_Ti_Hardware_991fb53395.jpg" alt="Phenomenex: BioTi Hardware" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Bio_Ti_Hardware_991fb53395.jpg 245w," sizes="100vw" width="1378" height="426"></p><h3><strong>4 Advanced Particle Platforms</strong></h3><p>All four of the Biozen particle platforms were individually designed and built by Phenomenex to take advantage of integral levels of performance, ruggedness, and reproducibility for protein characterization applications. Individually, each platform differs in the proprietary processing techniques used to control particle size and morphology.</p><p><img src="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg" alt="Phenomenex: Advanced Particle Platforms" srcset="https://storage.googleapis.com/labrulez-bucket-strapi-h3hsga3/thumbnail_Phenomenex_Advanced_Particle_Platforms_a0959aca03.jpg 245w," sizes="100vw" width="1439" height="868"></p>

Products from category GPC/SEC HPLC columns focused on Consumables distributed by Phenomenex - page 1

Related content

New blood biomarkers reveal how faithfully diabetes patients take metformin

Steroidal hormones and neurosteroids – novel therapeutic strategies in bacterial infections

EU Regulation 396/2005: Pesticide Residue Testing and the Critical Role of QuEChERS Evaporation in Food Safety